From Wikipedia, the free encyclopedia
(Redirected from DACRA)

Dual amylin and calcitonin receptor agonists (DACRAs) are a class of drugs that act as agonists at the amylin receptor and calcitonin receptor that are under development as therapies for obesity and type 2 diabetes. Examples are cagrilintide and the KBP family derived from salmon calcitonin, [1] including KBP‐042, [2] KBP-066A, [3] KBP-089, [4] and KBP-336. [5]

References

  1. ^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, M. A.; Henriksen, K. (December 2022). "Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi: 10.1016/j.biopha.2022.113842. ISSN  1950-6007. PMID  36242844.
  2. ^ Henriksen, Kim; Broekhuizen, Karen; de Boon, Wadim M. I.; Karsdal, Morten A.; Bihlet, Asger R.; Christiansen, Claus; Dillingh, Marlous R.; de Kam, Marieke; Kumar, Raj; Burggraaf, Jacobus; Kamerling, Ingrid M. C. (December 2021). "Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects". British Journal of Clinical Pharmacology. 87 (12): 4786–4796. doi: 10.1111/bcp.14921. ISSN  0306-5251. S2CID  235093884.
  3. ^ Andreassen, K. V.; Larsen, A. T.; Sonne, N.; Mohamed, K. E.; Karsdal, M. A.; Henriksen, K. (1 November 2021). "KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats". Molecular Metabolism. 53: 101282. doi: 10.1016/j.molmet.2021.101282. ISSN  2212-8778. PMC  8313742. PMID  34214708.
  4. ^ Larsen, Anna Thorsø; Gydesen, Sofie; Sonne, Nina; Karsdal, Morten Asser; Henriksen, Kim (7 January 2021). "The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile". BMC Endocrine Disorders. 21 (1): 10. doi: 10.1186/s12902-020-00678-2. ISSN  1472-6823. PMC  7791885. PMID  33413317.
  5. ^ Melander, Simone A.; Larsen, Anna T.; Elhady Mohamed, Khaled; Karsdal, Morten A.; Henriksen, Kim (20 June 2023). "840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats". Diabetes. 72 (Supplement_1). doi: 10.2337/db23-840-P. S2CID  259415731.


From Wikipedia, the free encyclopedia
(Redirected from DACRA)

Dual amylin and calcitonin receptor agonists (DACRAs) are a class of drugs that act as agonists at the amylin receptor and calcitonin receptor that are under development as therapies for obesity and type 2 diabetes. Examples are cagrilintide and the KBP family derived from salmon calcitonin, [1] including KBP‐042, [2] KBP-066A, [3] KBP-089, [4] and KBP-336. [5]

References

  1. ^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, M. A.; Henriksen, K. (December 2022). "Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi: 10.1016/j.biopha.2022.113842. ISSN  1950-6007. PMID  36242844.
  2. ^ Henriksen, Kim; Broekhuizen, Karen; de Boon, Wadim M. I.; Karsdal, Morten A.; Bihlet, Asger R.; Christiansen, Claus; Dillingh, Marlous R.; de Kam, Marieke; Kumar, Raj; Burggraaf, Jacobus; Kamerling, Ingrid M. C. (December 2021). "Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects". British Journal of Clinical Pharmacology. 87 (12): 4786–4796. doi: 10.1111/bcp.14921. ISSN  0306-5251. S2CID  235093884.
  3. ^ Andreassen, K. V.; Larsen, A. T.; Sonne, N.; Mohamed, K. E.; Karsdal, M. A.; Henriksen, K. (1 November 2021). "KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats". Molecular Metabolism. 53: 101282. doi: 10.1016/j.molmet.2021.101282. ISSN  2212-8778. PMC  8313742. PMID  34214708.
  4. ^ Larsen, Anna Thorsø; Gydesen, Sofie; Sonne, Nina; Karsdal, Morten Asser; Henriksen, Kim (7 January 2021). "The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile". BMC Endocrine Disorders. 21 (1): 10. doi: 10.1186/s12902-020-00678-2. ISSN  1472-6823. PMC  7791885. PMID  33413317.
  5. ^ Melander, Simone A.; Larsen, Anna T.; Elhady Mohamed, Khaled; Karsdal, Morten A.; Henriksen, Kim (20 June 2023). "840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats". Diabetes. 72 (Supplement_1). doi: 10.2337/db23-840-P. S2CID  259415731.



Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook